SEC RELEASES

FOR UPDATED
SEC FILINGS

for OWC Pharmaceutical
Research Corp.

OWCP

$0.0097
Friday, 14 May 2021

Company brief

Learn more about OWC Pharma

LATEST ANNOUNCEMENTS

November 26, 2019

Follow up letter to Stockholders

Read More
November 18, 2019

SCHEDULE 14A

OWC invites its stockholders to attend the Special Meeting on December 20, 2019, at 10:00 a.m., local time ,at the offices of Mintz, Levin, Cohn, Ferris, Glovsky & Popeo, P.C. at 666 Third Avenue , New York, New York 10017.

Read More
November 14, 2019

OWC and STENOCARE A/S have signed a strategic MoU

OWC and STENOCARE A/S have signed a strategic Memorandum of Understanding (MoU) to develop and commercialize new cannabis-based medical products. The new relationship will provide market access to OWC’s technologies and will accelerate STENOCAREs long term strategy to supplement its high quality generic medical cannabis products with differentiated products that are formulated to target specific patient groups suffering from specific conditions.
Read More
August 5, 2019

Israeli Medical Cannabis

OWC Pharma received long-awaited approval from the Israeli Medical Cannabis Agency to perform an efficacy study with OWC topical ointment on psoriatic patients. Currently, the study is planned to be conducted at the Kaplan Medical Center, an academic medical center in Israel.
Read More
February 11, 2019

To Our Shareholders

The last year was a critical year in which we laid the foundations for the sustainable success for our Company. We defined our strategy carefully and consolidated our positioning as a company which undertakes the research and development of fully validated medical products and pharmaceuticals based on cannabis.

Read More
December 31, 2018

FORM 10-K

The following documents (or parts thereof) are incorporated by reference into the following parts of this Form 10-K: Certain information required in Part III of this Annual Report on Form 10-K is incorporated from our definitive proxy statement for the 2019 annual meeting of stockholders to be filed pursuant to Regulation 14A with the Securities and Exchange Commission within 120 days of our fiscal year ended December 31, 2018.
Read More
December 16, 2018

Sublingual disintegrating tablet

OWC Pharma reports the successful production of its cannabinoid-enriched sublingual disintegrating tablet, specifically developed as smoking substitute.

Read More
November 19, 2019

Cannabis-based topical ointment

OWC Pharma reported that the first ever safety study of cannabis-based topical ointment, conducted at Shiba Academic Medical Center,  is close to completion as the last healthy volunteer started the treatment three weeks ago. The study is expected to be completed by the end of December 2018.

Read More

All rights Reserved. ©OWC2019

Linkedin
Close Menu